Search

Displaying results 2601 - 2610 of 2950 in total
  1. Drug

    Cyproterone acetate

    go.drugbank.com/drugs/DB04839
    ApprovedInvestigational

    An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estroge...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  2. Drug

    Ixabepilone

    go.drugbank.com/drugs/DB04845
    ApprovedInvestigational

    Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is ...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  3. Drug

    Tirapazamine

    go.drugbank.com/drugs/DB04858
    Investigational

    Tirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hy...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 Substrates
  4. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P).

  5. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2.

  6. Drug

    AN0128

    go.drugbank.com/drugs/DB05054
    Investigational

    Of particular importance is P. acnes and its causal role in acne vulgaris. The rise in antibiotic resistance of P. acnes to standard antibiotics necessitates the development of new treatment agents.

  7. Drug

    NN344

    go.drugbank.com/drugs/DB05115
    Experimental

    NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  8. Drug

    Pradefovir mesylate

    go.drugbank.com/drugs/DB05478
    Investigational

    Pradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver.

  9. Drug

    SN-38

    go.drugbank.com/drugs/DB05482
    Investigational

    7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan DB00762, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studyin...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  10. Drug

    Technetium Tc-99m ciprofloxacin

    go.drugbank.com/drugs/DB05488
    Experimental

    99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal absce...

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors